PTC Therapeutics
PTCTPTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.In September 2009, PTC entered into an agreement with R …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2023-2025
All insider trades at PTC Therapeutics
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 9/12/2025 | Sell | Boulding, Mark Elliott | EXEC. VP AND CLO | $61.5 | $1,508,083 |
| 9/11/2025 | Sell | Boulding, Mark Elliott | EXEC. VP AND CLO | $61.0 | $1,382,504 |
| 9/11/2025 | Sell | Reeve, Emma | Director | $59.5 | $934,448 |
| 9/9/2025 | Sell | Southwell, David P. | Director | $58.3 | $700,080 |
| 9/8/2025 | Sell | Pauwels, Eric | CHIEF BUSINESS OFFICER | $56.9 | $2,268,374 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)